Skip to content
← Back to this collection

PUBLICATIONS · 34320285

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2021 Jul 29
First author
Gnant M

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2021 Jul 29;385(5):462-463. doi: 10.1056/NEJMe2109356.
    note
    Source null
    related pmid
    34320293
    relationship
    Comment in
  2. citation
    Med. 2021 Sep 10;2(9):996-998. doi: 10.1016/j.medj.2021.08.010.
    note
    Source null
    related pmid
    35590193
    relationship
    Comment in

Authors and identifiers

  1. name
    Gnant M
    type
    Author
  2. name
    Fitzal F
    type
    Author
  3. name
    Rinnerthaler G
    type
    Author
  4. name
    Steger GG
    type
    Author
  5. name
    Greil-Ressler S
    type
    Author
  6. name
    Balic M
    type
    Author
  7. name
    Heck D
    type
    Author
  8. name
    Jakesz R
    type
    Author
  9. name
    Thaler J
    type
    Author
  10. name
    Egle D
    type
    Author
  11. name
    Manfreda D
    type
    Author
  12. name
    Bjelic-Radisic V
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Gnant M
    type
    Author
  2. name
    Fitzal F
    type
    Author
  3. name
    Rinnerthaler G
    type
    Author
  4. name
    Steger GG
    type
    Author
  5. name
    Greil-Ressler S
    type
    Author
  6. name
    Balic M
    type
    Author
  7. name
    Heck D
    type
    Author
  8. name
    Jakesz R
    type
    Author
  9. name
    Thaler J
    type
    Author
  10. name
    Egle D
    type
    Author
  11. name
    Manfreda D
    type
    Author
  12. name
    Bjelic-Radisic V
    type
    Author
bibliography ids
  1. nci-bib-000b33cd39aa57c719fd3cd3
book metadata
content sha256
0e577884555775c9dcb5bc40d207f9b61b8b5626623d73e5a03ab8899b2f1b31
document type
citation
dois
  1. 10.1056/NEJMoa2104162
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:34320285
immutable id
pubmed:34320285@0e577884555775c9dcb5bc40d207f9b61b8b5626623d73e5a03ab8899b2f1b31
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
5
name
The New England journal of medicine
nlm unique id
0255562
pages
395-405
volume
385
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2021 Jul 29;385(5):462-463. doi: 10.1056/NEJMe2109356.
    note
    Source null
    related pmid
    34320293
    relationship
    Comment in
  2. citation
    Med. 2021 Sep 10;2(9):996-998. doi: 10.1016/j.medj.2021.08.010.
    note
    Source null
    related pmid
    35590193
    relationship
    Comment in
outcomes validated
false
pmid
34320285
provenance
batch id
192b6392c165c6b06274
provider
NCBI PubMed ESummary
record sha256
8fc77d5cff8d7fbb678d74255d08d0e1bc76193fbb7d99bfd7f0d3a0b909c05d
response sha256
7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
retrieved at
2026-09-09T23:48:02.713075+00:00
publication date
display
2021 Jul 29
precision
day
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34320285/
title
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.

Preserved source evidence · Not medical advice